Aspa Therapeutics, a BridgeBio company, has released a November 17, 2026 update for the Canavan disease community regarding CANaspire, its clinical trial evaluating the investigational gene therapy BBP-812.
The update addresses a manufacturing issue that has delayed the production of new study material, with dosing currently anticipated to resume in mid-2027. Aspa Therapeutics also shares preliminary clinical trial findings, including changes in NAA biomarkers, motor function assessments, and safety observations among participants who have received the investigational therapy.
Read the full community letter below from the Aspa Therapeutics team for additional details about the manufacturing delay, trial progress, and next steps.
*The United Leukodystrophy Foundation is not liable for any inaccuracies or gaps in these overviews , which are offered “as is” without assurances on completeness, accuracy, or timeliness. For verification or detailed information, please consult the original articles directly.
As a leukodystrophy related nonprofit, the ULF provides awareness to scientific literature or news articles. Inclusion on our website does not imply endorsement of, or agreement with, the contents by the ULF.
